Plain-English translation of NCT06110572 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new combination of treatments for advanced small cell lung cancer. You would receive (an immunotherapy drug that helps your immune system fight cancer) combined with chemotherapy drugs and two types of radiation therapy. The goal is to see if adding radiation to this medication combination makes the treatment work better.
Advanced small cell lung cancer is a serious condition that needs better treatment options. Researchers believe that combining the medication with radiation therapy might help the immune system attack cancer more effectively and control the disease longer than standard treatments alone.
You likely qualify if…
You likely don't qualify if…
Over about 4 months, you would receive intravenous chemotherapy and immunotherapy drugs combined with two types of radiation therapy during an initial treatment phase. Then you would continue the immunotherapy medication alone for another 3 months. Throughout the trial and for up to 3 years after, you would have regular CT and MRI scans to monitor how the cancer responds, with follow-up visits every 3-4 months.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States